Dana-Farber Cancer Institute: Addition of CDK 4/6 Inhibitor Benefits Patients With HR+, HER2+ Metastatic Breast Cancer, New Study Shows
December 13, 2024
December 13, 2024
BOSTON, Massachusetts, Dec. 13 (TNSres) -- The Dana-Farber Cancer Institute issued the following news release:
The addition of a CDK 4/6 inhibitor to standard therapy in patients with "double-positive" metastatic breast cancer significantly extended the time the disease did not progress according to new data presented today at the San Antonio Breast Cancer Symposium. The results of the phase 3 PATINA trial presented by Otto Metzger, MD, medical oncologist at Dana-Farber Ca . . .
The addition of a CDK 4/6 inhibitor to standard therapy in patients with "double-positive" metastatic breast cancer significantly extended the time the disease did not progress according to new data presented today at the San Antonio Breast Cancer Symposium. The results of the phase 3 PATINA trial presented by Otto Metzger, MD, medical oncologist at Dana-Farber Ca . . .